More here:
Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh